Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Generics Office Finalizing Structure As Review Goals Approach

Executive Summary

Transition team leaders gain acting director titles, but “long and arduous” reorganization is not yet complete, CDER Director Woodcock notes.


Related Content

FDA Generics Office Hopes To Clear Unmeasured ANDAs
U.S. Generic Exclusivity Process To Go Public?
Pharmaceutical Quality And Generic Drugs: Janet Woodcock Explains Her Vision
FDA Generics Director’s Departure Shows Why Chemistry Matters





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts